ORLANDO, FL, May 19, 2002Cell Genesys, Inc. (Nasdaq: CEGE) today reported encouraging long term survival data from a Phase II multicenter clinical trial of GVAX prostate cancer vaccine which demonstrates a dose-dependent trend toward prolonged survival in patients with hormone refractory prostate cancer metastatic to bone. In the 34-patient study, seven of 10 (70 percent) patients receiving the higher dose level of the vaccine are alive 2.5 years after treatment (median survival greater than 30 months). Of the 24 patients receiving the lower dose of the vaccine, nine of 22 patients (41 percent) are alive 2.5 years after treatment (median survival 22 months), and two were lost to follow-up. These results compare favorably to the reported median survival of seven to 11 months for hormone refractory prostate cancer patients with bone metastases who are treated with chemotherapy, the current standard of care for this patient group. The dose-dependent improvement in survival was consistent with a previously reported improvement in time to disease progression measured by both radiologic and prostate-specific antigen (PSA) endpoints also in favor of the high dose group. Treatment with GVAX vaccine was safe and well tolerated. These data were presented at the American Society of Clinical Oncology (ASCO) Meeting in Orlando, FL by Jonathan Simons, M.D., of Emory University.

The study reported at ASCO employed a six-month treatment regimen in which patients received an initial "priming" dose of GVAX prostate cancer vaccine followed by 12 biweekly "booster doses using either a high dose or threefold lower dose regimen. The two dose groups were comparable with respect to disease stage, duration and prior treatment for their prostate cancer as well as other demographic criteria. The vaccine, which is a non patient-specific, off-the-shelf product was administered by an intradermal injection into the skin of the arms and legs in an outpatient clinic setting. Patien
'"/>

Contact: Claire Campbell
ccampbell@fkhealth.com
310-463-5047
Feinstein Kean Healthcare
19-May-2002

Page: 1 2 3 4
Related biology news :

1. Cell Genesys reports antitumor activity in Phase I/II GVAX lung cancer vaccine trial
2. UroGenesys researchers discover new target antigen for prostate cancers
3. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
4. Scientists question reports of massive ant supercolonies in California and Europe
5. Survey reports fall in stem cell transplants for breast cancer
6. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
7. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
8. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
9. Measles on the rise as vaccinations fall in the UK, Science study reports
10. WCS biologist George Schaller reports surprising increase in Tibets wildlife
11. Clinical study reports findings of combination therapy with DOXIL